Harmony Biosciences Holdings (NASDAQ: HRMY) confirmed that Chief Financial Officer Sandip Kapadia sold 3,746 shares of the company’s common stock on January 26, 2026, receiving a total of $139,171. The sales were carried out through a Rule 10b5-1 trading plan and executed at a weighted average price of $37.152 per share, with individual transactions ranging from $36.57 to $37.70.
After the disposition, Kapadia holds 24,521 shares directly in Harmony Biosciences. The company is currently valued at approximately $2.13 billion and is identified as having an "EXCELLENT" financial health score in external analytics referenced in company materials.
Market metrics highlighted by analysts show a trailing price-to-earnings ratio of 11.66 for the stock, which has been characterized as low relative to near-term earnings growth. Industry consensus among analysts is described as leaning bullish, and Harmony’s next scheduled earnings announcement is set for March 3.
Commercial performance and guidance
Harmony provided preliminary unaudited net product revenue figures for its lead product, WAKIX. The company reported approximately $243 million in WAKIX net product revenue for the fourth quarter of 2025 and about $868 million for the full year. Those figures represent year-over-year growth of 21% versus 2024.
Looking forward, Harmony projected 2026 WAKIX revenue in a range between $1.0 billion and $1.04 billion, a level the company said could place the product into blockbuster territory should the guidance be realized.
Clinical and strategic developments
On the clinical front, Harmony announced a collaboration with Beacon Biosignals to incorporate quantitative EEG measurements into two Phase 3 studies of HBS-301, which is being evaluated for narcolepsy and idiopathic hypersomnia.
The company also disclosed initial results from the Phase 3 ARGUS trial of EPX-100 for Dravet syndrome. Harmony said the preliminary data showed a median reduction in motor seizure frequency of approximately 50% among trial participants. These findings were presented at the American Epilepsy Society Annual Meeting.
Following the ARGUS data release, H.C. Wainwright reiterated a Buy rating on Harmony Biosciences and maintained a $55.00 price target.
Investor resources and next steps
For investors seeking additional analysis, the company’s coverage is available in extended research reports that encompass HRMY and a broad set of U.S. equities. The next earnings report on March 3 will provide updated financials and could inform near-term market reactions.